On the public citation graph

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

https://doi.org/10.1007/s00262-020-02613-9
0 signed · 142 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2019.1478openalex-snapshot
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.1002/9781118548387openalex-snapshot
Applied Logistic Regression
inferredcites →https://doi.org/10.1002/pst.1776openalex-snapshot
Effect of correlation on covariate selection in linear and nonlinear mixed effect models
inferredcites →https://doi.org/10.1007/978-1-4612-4380-9_25openalex-snapshot
Nonparametric Estimation from Incomplete Observations
inferredcites →https://doi.org/10.1007/s10637-019-00843-yopenalex-snapshot
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
inferredcites →https://doi.org/10.1016/0197-2456(96)00075-xopenalex-snapshot
A note on quantifying follow-up in studies of failure time
inferredcites →https://doi.org/10.1016/j.ajodo.2016.10.001openalex-snapshot
The chi-square test for trend
inferredcites →https://doi.org/10.1016/j.annonc.2019.11.015openalex-snapshot
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%
inferredcites →https://doi.org/10.1016/j.cllc.2015.02.006openalex-snapshot
Treatment of Elderly Patients With Non–Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
inferredcites →https://doi.org/10.1016/j.cllc.2019.05.009openalex-snapshot
First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non–small-cell Lung Cancer: A Systematic Review and Network Meta-analysis
inferredcites →https://doi.org/10.1016/j.ejca.2008.10.026openalex-snapshot
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
inferredcites →https://doi.org/10.1016/j.ejca.2017.01.004openalex-snapshot
Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas
inferredcites →https://doi.org/10.1016/j.ejca.2020.02.023openalex-snapshot
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
inferredcites →https://doi.org/10.1016/j.jtho.2016.10.007openalex-snapshot
Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
inferredcites →https://doi.org/10.1016/j.jtho.2017.07.031openalex-snapshot
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors
inferredcites →https://doi.org/10.1016/j.jtho.2019.08.483openalex-snapshot
OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1016/s0140-6736(18)32409-7openalex-snapshot
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
inferredcites →https://doi.org/10.1023/a:1018828709196openalex-snapshot
The Effect of Collinearity on Parameter Estimates in Nonlinear Mixed Effect Models
inferredcites →https://doi.org/10.1023/b:jopa.0000034404.86036.72openalex-snapshot
Power, Selection Bias and Predictive Performance of the Population Pharmacokinetic Covariate Model
inferredcites →https://doi.org/10.1038/modpathol.2015.63openalex-snapshot
Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
inferredcites →https://doi.org/10.1056/nejmoa1501824openalex-snapshot
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1606774openalex-snapshot
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1801005openalex-snapshot
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1810865openalex-snapshot
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1080/01621459.1958.10501452openalex-snapshot
Nonparametric Estimation from Incomplete Observations
inferredcites →https://doi.org/10.1080/0284186x.2020.1741678openalex-snapshot
Frequency of discordance in programmed death-ligand 1 (PD-L1) expression between primary tumors and paired distant metastases in advanced cancers: a systematic review and meta-analysis
inferredcites →https://doi.org/10.1080/10618600.1996.10474713openalex-snapshot
R: A Language for Data Analysis and Graphics
inferredcites →https://doi.org/10.1093/annonc/mdy014openalex-snapshot
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
inferredcites →https://doi.org/10.1093/annonc/mdz288openalex-snapshot
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
inferredcites →https://doi.org/10.1111/j.2517-6161.1972.tb00899.xopenalex-snapshot
Regression Models and Life-Tables
inferredcites →https://doi.org/10.1148/radiology.143.1.7063747openalex-snapshot
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
inferredcites →https://doi.org/10.1159/000453569openalex-snapshot
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
inferredcites →https://doi.org/10.1159/000455014openalex-snapshot
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
inferredcites →https://doi.org/10.1177/1758835918763493openalex-snapshot
PD-L1 expression testing in non-small cell lung cancer
inferredcites →https://doi.org/10.1186/s12967-019-1847-xopenalex-snapshot
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
inferredcites →https://doi.org/10.1186/s40425-019-0600-6openalex-snapshot
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
inferredcites →https://doi.org/10.1186/s40425-019-0793-8openalex-snapshot
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
inferredcites →https://doi.org/10.1200/jco.18.00149openalex-snapshot
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
inferredcites →https://doi.org/10.1200/jco.19.00189openalex-snapshot
Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
inferredcites →https://doi.org/10.18632/oncotarget.18703openalex-snapshot
Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis
inferredcites →https://doi.org/10.2217/imt-2019-0177openalex-snapshot
Outcomes of First-Line Pembrolizumab Monotherapy for PD-L1-Positive (TPS ≥50%) Metastatic NSCLC at US Oncology Practices
inferredcites →https://doi.org/10.2307/2281868openalex-snapshot
Nonparametric Estimation from Incomplete Observations
inferredcites →https://doi.org/10.2307/2344317openalex-snapshot
Asymptotically Efficient Rank Invariant Test Procedures
inferredcites →https://doi.org/10.2307/2348956openalex-snapshot
Statistical Methods for Psychology.
inferredcites →https://doi.org/10.3892/br.2019.1265openalex-snapshot
Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4852398openalex-extracted
inferred← citeshttps://doi.org/10.1002/cnr2.1739openalex-snapshot
Effectiveness of immunological agents in non‐small cell lung cancer
inferred← citeshttps://doi.org/10.1002/ijc.35445openalex-snapshot
Let's talk about sex: Survival among females and males in a real‐world cohort treated with pembrolizumab for non‐small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s00262-020-02757-8openalex-snapshot
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
inferred← citeshttps://doi.org/10.1007/s00262-020-02825-zopenalex-snapshot
PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung
inferred← citeshttps://doi.org/10.1007/s00262-021-03108-xopenalex-snapshot
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
inferred← citeshttps://doi.org/10.1007/s00262-022-03232-2openalex-snapshot
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
inferred← citeshttps://doi.org/10.1007/s00262-022-03359-2openalex-snapshot
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
inferred← citeshttps://doi.org/10.1007/s10238-024-01298-zopenalex-snapshot
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
inferred← citeshttps://doi.org/10.1007/s10555-024-10236-0openalex-snapshot
Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art
inferred← citeshttps://doi.org/10.1007/s10585-023-10217-7openalex-snapshot
Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s11864-021-00870-zopenalex-snapshot
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
inferred← citeshttps://doi.org/10.1007/s12325-022-02260-9openalex-snapshot
Characterizing the Shifting Real-World Treatment Landscape by PD-L1 Testing Status and Expression Level in Advanced Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/s12672-022-00538-6openalex-snapshot
Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis
inferred← citeshttps://doi.org/10.1007/s12672-024-01153-3openalex-snapshot
Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: a systematic review of real-world data
inferred← citeshttps://doi.org/10.1016/j.annonc.2021.08.1744openalex-snapshot
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
inferred← citeshttps://doi.org/10.1016/j.bonr.2022.101619openalex-snapshot
The road of NSCLC stem cells toward bone metastases
inferred← citeshttps://doi.org/10.1016/j.cllc.2020.06.010openalex-snapshot
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
inferred← citeshttps://doi.org/10.1016/j.cllc.2021.05.012openalex-snapshot
Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non–Small-Cell Lung Cancer and High PD-L1 Expression
inferred← citeshttps://doi.org/10.1016/j.cllc.2025.03.001openalex-snapshot
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018)
inferred← citeshttps://doi.org/10.1016/j.currproblcancer.2022.100947openalex-snapshot
Combination of immunotherapy, radiotherapy and denosumab as the best approach even for NSCLC poor prognosis patients: a case report with strong response, prolonged survival and a review of literature
inferred← citeshttps://doi.org/10.1016/j.ejca.2020.09.033openalex-snapshot
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index
inferred← citeshttps://doi.org/10.1016/j.ejca.2020.10.031openalex-snapshot
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients
inferred← citeshttps://doi.org/10.1016/j.ejca.2021.02.005openalex-snapshot
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
inferred← citeshttps://doi.org/10.1016/j.ejca.2021.03.041openalex-snapshot
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy
inferred← citeshttps://doi.org/10.1016/j.ejca.2021.05.016openalex-snapshot
Re: Comments on ‘High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non–small cell lung cancer patients’
inferred← citeshttps://doi.org/10.1016/j.esmoop.2021.100078openalex-snapshot
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.esmoop.2021.100355openalex-snapshot
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology
inferred← citeshttps://doi.org/10.1016/j.jtho.2026.103957openalex-snapshot
The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year Perspective
inferred← citeshttps://doi.org/10.1016/j.jtocrr.2023.100482openalex-snapshot
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1016/j.jtocrr.2026.100981openalex-snapshot
Clinical and Genomic Characteristics of Patients With Advanced NSCLC Who Have Long-Term Response to First-Line Immunotherapy: A Real-World Study
inferred← citeshttps://doi.org/10.1016/j.lungcan.2021.04.001openalex-snapshot
Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy
inferred← citeshttps://doi.org/10.1016/j.lungcan.2025.108482openalex-snapshot
Immunotherapy in advanced non-small cell lung cancer: What to do for the ‘Invisible’ patients after IPSOS trial results?
inferred← citeshttps://doi.org/10.1016/j.lungcan.2025.108580openalex-snapshot
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)
inferred← citeshttps://doi.org/10.1016/j.lungcan.2026.109490openalex-snapshot
Treatment-free survival after two-year immune checkpoint inhibitor treatment in non-small cell lung cancer: Utilizing the Korean Health Insurance Review and Assessment Service database
inferred← citeshttps://doi.org/10.1016/j.neo.2025.101224openalex-snapshot
Contribution of the immune bone marrow microenvironment to tumor growth and bone deconstruction: implications for improving immunotherapeutic strategies in bone metastasis
inferred← citeshttps://doi.org/10.1038/s41598-023-36623-1openalex-snapshot
Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting
inferred← citeshttps://doi.org/10.1080/14737140.2020.1816173openalex-snapshot
Promising predictors of checkpoint inhibitor response in NSCLC
inferred← citeshttps://doi.org/10.1080/14796694.2026.2709201openalex-snapshot
Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience
inferred← citeshttps://doi.org/10.1080/17476348.2024.2302356openalex-snapshot
First-line immunotherapy in non-small cell lung cancer: how to select and where to go
inferred← citeshttps://doi.org/10.1097/cji.0000000000000340openalex-snapshot
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50%
inferred← citeshttps://doi.org/10.1097/cji.0000000000000490openalex-snapshot
Three-Year Overall Survival of Patients With Advanced Non–Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study)
inferred← citeshttps://doi.org/10.1111/1759-7714.13852openalex-snapshot
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
inferred← citeshttps://doi.org/10.1111/1759-7714.14256openalex-snapshot
Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy
inferred← citeshttps://doi.org/10.1136/bmjopen-2023-076715openalex-snapshot
Pembrolizumab monotherapy for non-small cell lung cancer (NSCLC): can patient stratification be improved in the UK Tayside population? A retrospective cohort study
inferred← citeshttps://doi.org/10.1136/jitc-2020-001403openalex-snapshot
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
inferred← citeshttps://doi.org/10.1136/jitc-2021-002421openalex-snapshot
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
inferred← citeshttps://doi.org/10.1136/jitc-2021-003536openalex-snapshot
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1136/jitc-2024-010674openalex-snapshot
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
inferred← citeshttps://doi.org/10.1155/2021/8820691openalex-snapshot
Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1
inferred← citeshttps://doi.org/10.1155/2021/8970173openalex-snapshot
Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation
inferred← citeshttps://doi.org/10.1155/2023/4477263openalex-snapshot
Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1158/0008-5472.can-23-0161openalex-snapshot
Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
inferred← citeshttps://doi.org/10.1177/17588359211010937openalex-snapshot
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1177/17588359231195600openalex-snapshot
Pursuit or discontinuation of anti-PD1 after 2 years of treatment in long-term responder patients with non-small cell lung cancer
inferred← citeshttps://doi.org/10.1186/s12885-026-16433-0openalex-snapshot
Leveraging data-driven risk-adapted surveillance strategies after disease progression in locally advanced rectal cancer
inferred← citeshttps://doi.org/10.1186/s13014-026-02855-4openalex-snapshot
Outcome of patients with lung cancer treated with stereotactic body radiotherapy for bone oligometastases - a European multicenter cohort study
inferred← citeshttps://doi.org/10.1186/s13045-022-01226-2openalex-snapshot
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
inferred← citeshttps://doi.org/10.21037/tlcr-21-15openalex-snapshot
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.21037/tlcr-22-852openalex-snapshot
Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV)
inferred← citeshttps://doi.org/10.21203/rs.3.rs-4254848/v1openalex-snapshot
Comparison of Efficacy, safety, and cost-effectiveness of pembrolizumab versus chemotherapy for patients with advanced non-small cell lung cancer: a real-world study
inferred← citeshttps://doi.org/10.2147/cmar.s376510openalex-snapshot
Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy
inferred← citeshttps://doi.org/10.2217/imt-2021-0038openalex-snapshot
Body Composition and Inflammation Impact in Non-Small-Cell Lung Cancer Patients Treated by First-line Immunotherapy
inferred← citeshttps://doi.org/10.2340/1651-226x.2024.20309openalex-snapshot
First-line Treatment Patterns and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden: A Population-based Real-world Study with Focus on Immunotherapy
inferred← citeshttps://doi.org/10.2478/raon-2026-0050openalex-snapshot
Real-world data survival outcomes of first line immunotherapy with pembrolizumab in high expressers with stage IV non-small cell lung cancer
inferred← citeshttps://doi.org/10.29011/2574-710x.10147openalex-snapshot
Pembrolizumab with or without Chemotherapy for First-Line Palliative Treatment for PD-L1 High-Positive Advanced Non-Small Cell Lung Cancer: A Monocentric Analysis
inferred← citeshttps://doi.org/10.3389/fmed.2025.1635626openalex-snapshot
Pembrolizumab in the treatment of non-small cell lung cancer—experiences from clinical practice
inferred← citeshttps://doi.org/10.3389/fnut.2023.1213255openalex-snapshot
Identification of prognostic nutritional index as a reliable prognostic indicator for advanced lung cancer patients receiving immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.3389/fonc.2021.670230openalex-snapshot
Evaluation of the Lung Immune Prognostic Index in Non-Small Cell Lung Cancer Patients Treated With Systemic Therapy: A Retrospective Study and Meta-Analysis
inferred← citeshttps://doi.org/10.3389/fonc.2021.685047openalex-snapshot
Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.3389/fonc.2022.834761openalex-snapshot
Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1
inferred← citeshttps://doi.org/10.3389/fonc.2022.978069openalex-snapshot
Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3389/fonc.2023.1044327openalex-snapshot
Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3389/fonc.2024.1415470openalex-snapshot
Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3389/fonc.2024.1510278openalex-snapshot
First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study
inferred← citeshttps://doi.org/10.3389/fonc.2025.1615795openalex-snapshot
Systematic literature review of real-world evidence on overall survival in cancer patients before and after the approval of anti-PD-(L)1 therapy
inferred← citeshttps://doi.org/10.3390/biomedicines13051175openalex-snapshot
Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia
inferred← citeshttps://doi.org/10.3390/biomedicines14081681openalex-snapshot
Bridging the Gap in Lung Cancer: Novel Biomarkers, Metabolic Drivers, and Advanced Therapeutics from Bench to Bedside
inferred← citeshttps://doi.org/10.3390/cancers13194846openalex-snapshot
Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy
inferred← citeshttps://doi.org/10.3390/cancers14010075openalex-snapshot
Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.3390/cancers16101802openalex-snapshot
Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study)
inferred← citeshttps://doi.org/10.3390/cancers17223643openalex-snapshot
Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study)
inferred← citeshttps://doi.org/10.3390/curroncol30060402openalex-snapshot
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
inferred← citeshttps://doi.org/10.3390/curroncol32040229openalex-snapshot
Long-Term Outcomes in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression
inferred← citeshttps://doi.org/10.3390/curroncol33040215openalex-snapshot
First-Line Pembrolizumab Monotherapy for Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Study from Vietnam
inferred← citeshttps://doi.org/10.3390/jcm10051005openalex-snapshot
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab
inferred← citeshttps://doi.org/10.3390/jcm12051833openalex-snapshot
Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review
inferred← citeshttps://doi.org/10.3390/jcm14176200openalex-snapshot
Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%)
inferred← citeshttps://doi.org/10.3390/jcm15124757openalex-snapshot
Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study
inferred← citeshttps://doi.org/10.37349/etat.2021.00030openalex-snapshot
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
inferred← citeshttps://doi.org/10.37349/etat.2021.00043openalex-snapshot
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis
inferred← citeshttps://doi.org/10.3892/ijo.2024.5623openalex-snapshot
Immunotherapy targeting PD‑1/PD‑L1: A potential approach for the treatment of cancer bone metastases (Review)
inferred← citeshttps://doi.org/10.4236/abb.2023.144010openalex-snapshot
Value of 18F-FDG PET/CT Based on PD-L1 to Predict Outcomes of Immunotherapy in NSCLC
inferred← citeshttps://doi.org/10.54337/aau515553116openalex-snapshot
LEARNING FROM THE PAST: OPTIMIZING FUTURE USE OF IMMUNE CHECKPOINT INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER
inferred← citeshttps://doi.org/10.6004/jnccn.2020.7668openalex-snapshot
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.6084/m9.figshare.18865030openalex-snapshot
Additional file 1 of High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
inferred← citeshttps://doi.org/10.62347/lqwy8309openalex-snapshot
Efficacy and safety of pembrolizumab in the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.